Duke Licenses NPM1 from Trovagene for AML Research, Testing | GenomeWeb

NEW YORK (GenomeWeb News) – Trovagene today announced it has granted Duke University and Duke University Health Systems a non-exclusive license covering the use of the nucleophosmin protein (NPM1).

The agreement allows Duke to incorporate NPM1 into research and clinical testing services for acute myelogenous leukemia. The terms of the deal includes upfront payments and royalties. Further details were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.